S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
NASDAQ:BOLT

Bolt Biotherapeutics - BOLT Stock Forecast, Price & News

$2.49
+0.09 (+3.75%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.36
$2.50
50-Day Range
$1.70
$2.61
52-Week Range
$1.39
$19.28
Volume
62,626 shs
Average Volume
132,040 shs
Market Capitalization
$93.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

Bolt Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
863.9% Upside
$24.00 Price Target
Short Interest
Healthy
4.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1.60 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.87) to ($2.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

242nd out of 1,283 stocks

Pharmaceutical Preparations Industry

103rd out of 615 stocks

BOLT stock logo

About Bolt Biotherapeutics (NASDAQ:BOLT) Stock

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Bolt Biotherapeutics Stock Performance

Shares of BOLT traded up $0.09 during mid-day trading on Friday, reaching $2.49. 62,626 shares of the company's stock were exchanged, compared to its average volume of 132,040. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.16 and a quick ratio of 10.16. The stock has a market capitalization of $93.30 million, a PE ratio of -0.94 and a beta of 0.99. The business's fifty day simple moving average is $2.14 and its 200-day simple moving average is $2.48. Bolt Biotherapeutics has a 52-week low of $1.39 and a 52-week high of $19.28.

Bolt Biotherapeutics (NASDAQ:BOLT - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $0.07. The firm had revenue of $0.81 million during the quarter, compared to analysts' expectations of $1.38 million. On average, equities research analysts expect that Bolt Biotherapeutics will post -2.87 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BOLT shares. Stifel Nicolaus dropped their price objective on shares of Bolt Biotherapeutics from $16.00 to $13.00 in a report on Friday, May 13th. Morgan Stanley dropped their price objective on shares of Bolt Biotherapeutics to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, May 17th.

Insider Buying and Selling at Bolt Biotherapeutics

In other Bolt Biotherapeutics news, major shareholder Holdings A/S Novo sold 800,000 shares of the firm's stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $2.00, for a total value of $1,600,000.00. Following the completion of the sale, the insider now owns 3,703,991 shares of the company's stock, valued at $7,407,982. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 22.90% of the stock is owned by corporate insiders.

Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Stock News Headlines

Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics Stock Halves on Mediocre Trial Data
Why Bolt Biotherapeutics Stock Crashed Today
See More Headlines
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Company Calendar

Last Earnings
5/12/2022
Today
8/07/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BOLT
CUSIP
09769810
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+863.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-98,590,000.00
Pretax Margin
-4,718.52%

Debt

Sales & Book Value

Annual Sales
$1.26 million
Book Value
$6.71 per share

Miscellaneous

Free Float
28,891,000
Market Cap
$93.30 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Dr. Randall C. Schatzman Ph.D. (Age 67)
    CEO & Director
    Comp: $830.67k
  • Dr. Edgar G. Engleman M.D. (Age 76)
    Founder & Independent Director
    Comp: $31.58k
  • Mr. William P. Quinn (Age 51)
    CFO & Sec.
    Comp: $563.68k
  • Mr. Grant Yonehiro C.F.A. (Age 58)
    M.B.A., Chief Bus. Officer
    Comp: $519.98k
  • Dr. Edith A. Perez M.D. (Age 65)
    Chief Medical Officer
    Comp: $627.32k
  • Dr. David Dornan Ph.D. (Age 44)
    Advisor
    Comp: $580.08k
  • Ms. Karen L. Bergman
    VP of Communications & Investor Relations
  • Mr. Wesley Burwell
    VP & Head of HR
  • Dr. Nathan Ihle Ph.D.
    Sr. VP of Pharmaceutical Operations
  • Mr. Bruce Hug M.D.
    Ph.D., Sr. VP of Clinical Devel. & Translational Medicine













BOLT Stock - Frequently Asked Questions

Should I buy or sell Bolt Biotherapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bolt Biotherapeutics stock.
View analyst ratings for Bolt Biotherapeutics
or view top-rated stocks.

What is Bolt Biotherapeutics' stock price forecast for 2022?

4 brokerages have issued 1-year price targets for Bolt Biotherapeutics' stock. Their BOLT stock forecasts range from $5.00 to $45.00. On average, they expect Bolt Biotherapeutics' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 863.9% from the stock's current price.
View analysts' price targets for Bolt Biotherapeutics
or view top-rated stocks among Wall Street analysts.

How has Bolt Biotherapeutics' stock performed in 2022?

Bolt Biotherapeutics' stock was trading at $4.90 on January 1st, 2022. Since then, BOLT stock has decreased by 49.2% and is now trading at $2.49.
View the best growth stocks for 2022 here
.

When is Bolt Biotherapeutics' next earnings date?

Bolt Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Bolt Biotherapeutics
.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) issued its quarterly earnings data on Thursday, May, 12th. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.07. The business had revenue of $0.81 million for the quarter, compared to analyst estimates of $1.38 million.

What other stocks do shareholders of Bolt Biotherapeutics own?

When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.74%), Russell Investments Group Ltd. (0.26%) and Marquette Asset Management LLC (0.17%). Company insiders that own Bolt Biotherapeutics stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn.
View institutional ownership trends for Bolt Biotherapeutics
.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bolt Biotherapeutics' stock price today?

One share of BOLT stock can currently be purchased for approximately $2.49.

How much money does Bolt Biotherapeutics make?

Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $93.30 million and generates $1.26 million in revenue each year. The company earns $-98,590,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does Bolt Biotherapeutics have?

Bolt Biotherapeutics employs 91 workers across the globe.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for Bolt Biotherapeutics is www.boltbio.com. The company can be reached via phone at 650-665-9295 or via email at sarah.mccabe@sternir.com.

This page (NASDAQ:BOLT) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.